Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND)
RecruitingOBSERVATIONAL
Enrollment
200
Participants
Timeline
Start Date
December 4, 2023
Primary Completion Date
June 30, 2025
Study Completion Date
June 30, 2027
Conditions
DLBCL - Diffuse Large B Cell Lymphoma
Trial Locations (1)
20122
RECRUITING
Incyte Biosciences Italy S.r.l, Milan
All Listed Sponsors
collaborator
Advice Pharma Group srl
INDUSTRY
lead
Incyte Biosciences Italy S.r.l
INDUSTRY
NCT06299553 - Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND) | Biotech Hunter | Biotech Hunter